**Core Concept**
Omalizumab is a recombinant humanized monoclonal antibody used in the treatment of severe allergic asthma. It targets **IgE**, a key player in allergic reactions. This mechanism is crucial for its therapeutic effect.

**Why the Correct Answer is Right**
Omalizumab works by binding to **IgE**, thus preventing it from interacting with the **high-affinity IgE receptor (FcεRI)** on mast cells and basophils. This interaction is essential for the allergic response, as it leads to the release of **histamine** and other mediators, causing allergic symptoms. By inhibiting this pathway, omalizumab reduces the frequency and severity of asthma exacerbations.

**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because it does not specify the mechanism or target of omalizumab.
**Option B:** Incorrect as it is unrelated to the mechanism of action of omalizumab.
**Option C:** Incorrect because, although omalizumab is used in asthma, this option does not describe its pharmacological action.
**Option D:** Incorrect because it is not a description of omalizumab's mechanism of action.

**Clinical Pearl / High-Yield Fact**
Omalizumab is particularly useful in patients with severe persistent allergic asthma who have a high **IgE level** and are inadequately controlled with inhaled corticosteroids. Its use can significantly reduce the need for oral corticosteroids and improve quality of life.

**Correct Answer:** D. an anti-IgE antibody.